Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zishen Jianpi Huayu is a traditional Chinese medicine (TCM) formula, most commonly available as a tablet formulation. It is composed of multiple herbal ingredients and is used primarily for the adjunctive treatment of diabetic complications such as diabetic retinopathy and chronic renal insufficiency. The mechanism of action involves modulation of inflammatory pathways and vascular factors; key active components include quercetin, kaempferol, and rehmannia flavonoids. These act on targets such as interleukin-1β (IL-1β), interleukin-6 (IL-6), vascular endothelial growth factor A (VEGFA), AKT1, TP53, and are involved in signaling pathways like NF-κB, AGE-RAGE, and PI3K-AKT. Experimental studies have shown that the formula can reduce inflammation in human retinal microvascular endothelial cells under high-glucose conditions[2]. Clinical studies suggest efficacy in improving kidney function parameters in chronic renal insufficiency[3]. The product is developed within the framework of TCM by various Chinese research institutions but specific commercial developers or manufacturers are not clearly identified from available sources.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zishen Jianpi Huayu.